Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 113-118

  Kang, Moo Rim ^a   Kang, Jong Soon ^a   Yang, Jeong Wook ^a   Kim, Bo Geun ^a   Kim, Jin Ah ^a   Jo, Yeong Nang ^a   Lee, Kiho ^a   Lee, Chang Woo ^a   Lee, Ki Hoon ^a   Yun, Jieun ^a   Kim, Hwan Mook ^a   Han, Gyoonhee ^b   Kang, Jong Seong ^c   Park, Song Kyu ^d  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Yonsei University   (South Korea)

^c Chungnam National University   (South Korea)

^d Korea University   (South Korea)

Author keywords

Apoptosis; Cell cycle arrest; Histone deacetylase inhibitor; Microarray

Indexed keywords

CARD DOMAIN CONTAINING PROTEIN; CASPASE 3; CASPASE 7; HARAKIRI PROTEIN; HISTONE DEACETYLASE INHIBITOR; KBH A42; ONCOPROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 10B; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY 8; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION;

EID: 84855230127     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.430     Document Type: Article

References (22)

1. Saito A, Yamashita T, Mariko Y, et al: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96: 4592-4597, 1999.
2. Saunders NA, Popa C, Serewko MM, Jones SJ, Dicker AJ and Dahler AL: Histone deacetylase inhibitors: novel anticancer agents. Expert Opin Investig Drugs 8: 1611-1621, 1999.
3. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.
4. Chambers AE, Banerjee S, Chaplin T, et al: Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 39: 1165-1175, 2003.
5. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG and Davidsen SK: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163, 2003.
6. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101: 540-545, 2004.
7. Peart MJ, Smyth GK, van Laar RK, et al: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 3697-3702, 2005.
8. Sasakawa Y, Naoe Y, Sogo N, et al: Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69: 603-616, 2005.
9. Gray SG, Qian CN, Furge K, Guo X and Teh BT: Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 24: 773-795, 2004.
10. Butler LM, Agus DB, Scher HI, et al: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170, 2000.
11. Richon VM, Sandhoff TW, Rifkind RA and Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019, 2000.
12. Kang MR, Kang JS, Han SB, et al: A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells. Biochem Pharmacol 78: 486-494, 2009.
13. Kang MR, Lee K, Kang JS, et al: KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein. Oncol Rep 23: 801-809, 2010.
14. Lee SD, Park SK, Lee ES, et al: A lipid-soluble red ginseng extract inhibits the growth of human lung tumor xenografts in nude mice. J Med Food 13: 1-5, 2010.
15. Louis M, Rosato RR, Brault L, et al: The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. Int J Oncol 25: 1701-1711, 2004.
16. Doi S, Soda H, Oka M, et al: The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 3: 1397-1402, 2004.
17. Roh MS, Kim CW, Park BS, et al: Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis 9: 583-589, 2004.
18. Willis SN and Adams JM: Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17: 617-625, 2005.
19. Inohara N, Ding L, Chen S and Nunez G: Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 16: 1686-1694, 1997.
20. Takimoto R and El-Deiry WS: Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19: 1735-1743, 2000.
21. Stehlik C, Lee SH, Dorfleutner A, Stassinopoulos A, Sagara J and Reed JC: Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation. J Immunol 171: 6154-6163, 2003.
22. Staber PB, Noehammer C, Durkop H, et al: mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma. Leuk Res 30: 343-348, 2006.